- Home
- BCAB vs AFMD Comparison
BCAB vs AFMD Comparison
Compare BCAB & AFMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- AFMD
- Stock Information
- Founded
- BCAB 2007
- AFMD 2000
- Country
- BCAB United States
- AFMD Germany
- Employees
- BCAB N/A
- AFMD N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- AFMD Biotechnology: Pharmaceutical Preparations
- Sector
- BCAB Health Care
- AFMD Health Care
- Exchange
- BCAB Nasdaq
- AFMD Nasdaq
- Market Cap
- BCAB 96.2M
- AFMD 53.3M
- IPO Year
- BCAB 2020
- AFMD 2014
- Fundamental
- Price
- BCAB $2.08
- AFMD $3.36
- Analyst Decision
- BCAB Strong Buy
- AFMD Strong Buy
- Analyst Count
- BCAB 2
- AFMD 5
- Target Price
- BCAB $6.00
- AFMD $16.25
- AVG Volume (30 Days)
- BCAB 1.6M
- AFMD 80.0K
- Earning Date
- BCAB 11-08-2024
- AFMD 11-12-2024
- Dividend Yield
- BCAB N/A
- AFMD N/A
- EPS Growth
- BCAB N/A
- AFMD N/A
- EPS
- BCAB N/A
- AFMD N/A
- Revenue
- BCAB N/A
- AFMD $7,959,927.00
- Revenue This Year
- BCAB N/A
- AFMD N/A
- Revenue Next Year
- BCAB N/A
- AFMD $48.98
- P/E Ratio
- BCAB N/A
- AFMD N/A
- Revenue Growth
- BCAB N/A
- AFMD N/A
- 52 Week Low
- BCAB $1.14
- AFMD $2.92
- 52 Week High
- BCAB $4.02
- AFMD $8.95
- Technical
- Relative Strength Index (RSI)
- BCAB 55.80
- AFMD 44.84
- Support Level
- BCAB $1.87
- AFMD $3.28
- Resistance Level
- BCAB $2.13
- AFMD $3.51
- Average True Range (ATR)
- BCAB 0.12
- AFMD 0.17
- MACD
- BCAB 0.00
- AFMD 0.04
- Stochastic Oscillator
- BCAB 68.90
- AFMD 55.79
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About AFMD Affimed N.V.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.